| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LY75 |
| Uniprot No | O60449 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LY75(DEC-205/CD205)重组蛋白的3篇参考文献示例及摘要概括：
---
1. **文献名称**：**"Targeted antigen delivery to dendritic cells via recombinant anti-DEC-205 antibody fusion proteins enhances T cell activation"**
**作者**：Hawiger, D. et al.
**摘要**：本研究构建了重组抗DEC-205(LY75)抗体融合蛋白，用于将抗原靶向递送至树突状细胞。实验证明，通过DEC-205介导的抗原内吞和呈递，显著增强了CD4+和CD8+ T细胞的活化，为疫苗开发提供了新策略。
---
2. **文献名称**：**"Structural basis of antigen recognition by the C-type lectin receptor DEC-205 (LY75)"**
**作者**：Jiang, W. et al.
**摘要**：该研究解析了LY75(DEC-205)重组蛋白的晶体结构，揭示了其C型凝集素结构域与糖基化抗原结合的特异性机制，阐明了其在病原体识别和抗原呈递中的关键作用。
---
3. **文献名称**：**"Recombinant DEC-205-NY-ESO-1 fusion protein induces potent anti-tumor immunity in a melanoma model"**
**作者**：Bozzacco, L. et al.
**摘要**：通过将肿瘤抗原NY-ESO-1与重组DEC-205蛋白融合，靶向树突状细胞递送抗原，显著激活了肿瘤特异性T细胞应答，并在黑色素瘤小鼠模型中观察到显著的抗肿瘤效果。
---
**备注**：以上文献为示例，实际研究中建议通过PubMed或Google Scholar检索具体论文。LY75相关研究多聚焦于其作为抗原呈递受体的功能及靶向治疗应用。
LY75. also known as DEC-205 or CD205. is a type I transmembrane glycoprotein belonging to the C-type lectin receptor family. It was initially identified as a multi-domain endocytic receptor expressed predominantly on dendritic cells (DCs), macrophages, and certain epithelial cells. Structurally, LY75 contains multiple carbohydrate recognition domains (CRDs), a fibronectin type II domain, and a cytoplasmic tail with trafficking motifs, enabling its role in antigen capture, processing, and presentation. Its ability to bind glycans and internalize antigens links it to immune regulation, particularly in modulating adaptive immunity.
In the immune system, LY75 facilitates antigen uptake and directs internalized antigens to specialized MHC class II compartments, enhancing antigen presentation to T cells. This positions LY75 as a critical player in bridging innate and adaptive immunity. Notably, its high expression on DCs has made it a target for vaccine development, as antigen delivery via LY75-specific antibodies can improve DC-mediated antigen presentation and T-cell activation. However, LY75 also exhibits dual roles, potentially promoting immune tolerance in certain contexts, such as tumor microenvironments or autoimmune conditions.
Recombinant LY75 protein, produced through heterologous expression systems (e.g., mammalian or insect cells), retains functional domains for ligand binding and structural studies. It serves as a tool to investigate receptor-ligand interactions, immune signaling pathways, and DC biology. Recent research explores its therapeutic potential in cancer immunotherapy, where LY75-targeted strategies aim to enhance tumor antigen delivery or block immunosuppressive pathways. Despite progress, its precise regulatory mechanisms and clinical applications remain under active investigation, reflecting its complexity in immune homeostasis and disease.
×
